Alliance Global Partners analyst Scott Henry initiated coverage of MediWound (MDWD) with a Buy rating and $25 price target The Israel-based company is developing, manufacturing, and marketing wound care treatments and sells the NexoBrid therapy for burn care. The firm’s Buy rating is based on an expected near-term manufacturing capacity increase to expand NexoBrid sales, while longer-term it believes that the pipeline drug EscharEx could be “a transformative new product that could drive sustained profitability,” the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDWD:
- MediWound to present ExcharEx data at wound care conferences
- MediWound Announces 2025 Annual General Meeting and Key Agenda Items
- MediWound’s Earnings Call: Progress Amid Financial Challenges
- Optimistic Buy Rating for Mediwound: Strong Financials and Strategic Growth Initiatives Highlight Promising Future
- Strategic Advancements and Market Potential Drive Buy Rating for Mediwound